



FOR IMMEDIATE RELEASE

Profectus BioSciences, Inc. is Awarded a Phase II SBIR Totaling \$2.8 Million to Develop Therapeutic Vaccines Against HIV

BALTIMORE, Md., October 21, 2015 – Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a Phase II Small Business Innovative Research grant from the Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH. This award supports the optimization and testing of a novel DNA vaccine strategy as a therapeutic vaccine against SIV infection of macaques, the prevailing animal model for HIV, in collaboration with Dr. Deborah Fuller, Associate Professor in Microbiology at the University of Washington. The effort builds on Dr. Fuller’s key observation that a skin-delivered therapeutic DNA vaccine co-formulated with a novel adjuvant stimulated mucosal T cell responses in SIV-infected macaques and led to durable viral suppression in these animals after stopping antiretroviral drug therapy (ART). As a component of the National Institutes of Health’s HIV “Cure Agenda,” this collaboration aims to improve this outcome by using more potent adjuvants from the Profectus portfolio and a novel DNA delivery device that more efficiently delivers DNA into the skin. The animal work is being conducted at the Washington National Primate Research Center in Seattle, Washington.

About Profectus BioSciences

Profectus BioSciences is a clinical-stage vaccine company developing innovative vaccines for the prevention and treatment of infectious diseases and the treatment of cancer. Profectus vaccines are based on the company’s proprietary VesiculoVax™ and DNA vaccine delivery platforms. Used alone, the first-in-class VesiculoVax™-vectored vaccines lead to rapid expansion of B cells to provide protection against emerging infectious diseases of public health and biodefense importance such as Ebola, Marburg, Chikungunya, and the Equine Encephalitis viruses. When used as a boost after priming the immune system with best-in-class pDNA vaccines, VesiculoVax™-vectored vaccines lead to the expansion of primed T cells into effector cells that are uniquely suited to killing virally infected cells and cancers. Current programs using the Prime/Boost System of Vaccines (PBS Vax™) strategy include hepatitis B virus (HBV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV-2), and human immunodeficiency virus (HIV). Partners and collaborators include the Galveston National Laboratory at UTMB, Yale University, the Institute of Human Virology, the Center for HIV/AIDS Vaccine Immunology, the National Cancer Institute, the NIH Division of AIDS, the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative, the HIV Vaccines Trials Network, and the AIDS Clinical Trials Group. Profectus has been funded by Cross Atlantic Capital Partners (“XACP”) of Radnor, Pennsylvania. XACP’s primary investor is the

Pennsylvania Public School Employees' Retirement System (PSERS). For more information, please visit www.profectusbiosciences.com.

###

Contact:

Jeffrey N. Meshulam

President

Profectus BioSciences, Inc.

443-743-1100

Meshulam@profectusbiosciences.com